Soc. Security Admin. Seeks Industry Help In Speeding Orphan Drug Coverage
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sponsors of drugs to treat disabling illnesses have an opportunity to work with the Social Security Administration to simplify eligibility determinations that could in turn make it easier for patients to obtain Medicare coverage for their treatments
You may also be interested in...
"Regulatory Predictability" Is Key Barrier To Orphan Drug Development, Social Security Head Astrue Says
FDA's new leadership should focus on improving the "regulatory predictability" for orphan drug development, Social Security Administration Commissioner Michael Astrue said during a discussion of orphan drug policy sponsored by Shire Pharmaceuticals, the National Chamber Foundation and the U.S. Chamber of Conference in Washington, D.C. June 5
US FDA Alzheimer Guidance Update Reflects Changes In Biomarkers – And Leadership
Latest update to draft guidance on early Alzheimer’s drug development is the third iteration of a document first published in 2013. The history of the guidance is a reflection of structural and leadership changes in the neurology review team at FDA.